All In Biotech

Free tool

FAERS Monitor: Tyenne

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761275 or its brand name (Tyenne, Tocilizumab-Aazg). Reports on generic versions are filed under their own applications.

Reports

616

Serious

358

58% of reports

Hospitalization

160

Death reported

30

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective42
  • headache41
  • arthralgia40
  • pain39
  • pruritus38
  • urticaria36
  • rheumatoid arthritis31
  • rash28
  • fatigue27
  • death25
  • product substitution issue23
  • anaphylactic reaction22
  • off label use20
  • peripheral swelling19
  • diarrhoea18

Reports by year received

View as table
YearReports
20202
20212
20234
202453
2025186
2026369

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,543 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product substitution issueSignal2313.69.1258
anaphylactic reactionSignal2213.69.0245
rheumatoid arthritisSignal319.36.6223
urticariaSignal367.35.3192
peripheral swellingSignal194.22.744
pruritusSignal383.42.562
arthralgiaSignal403.32.463
headacheSignal412.21.728
rashSignal282.21.517
painSignal392.21.624
fatigue271.20.81
drug ineffective421.10.80
death251.00.70
diarrhoea181.00.60
off label use200.80.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.